Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Worldwide Antimalarial Resistance Network (WWARN), hosted by NDM’s Centre for Tropical Medicine and Global Health, have provided unique insights into the epidemiology of malaria in pregnancy. The study explored the relationship between infection and fever and found that submicroscopic malaria was associated with fever in Africa but not in Asia and the Americas.

A pregnant African woman sitting against a wall © Doune Porter-GAVI

Malaria infections during pregnancy can cause adverse birth outcomes, yet many infections are undetected by microscopy. Submicroscopic malaria infections are infections which are below the limit of detection of microscopy but can be detected by sensitive methods like polymerase chain reaction and loop-mediated isothermal amplification.

Previously data in this area were scarce, but this new systematic review published in The Lancet, by 107 researchers collaborating with WWARN provides a more detailed global picture. Researchers used aggregated data from 23 studies and 45 datasets, published between 1997 and 2021, from the WWARN Malaria in Pregnancy (MiP) Library.

They found submicroscopic malaria in pregnancy occurred in all malarious regions of the world and was more common than microscopic malaria in most settings. Similar to reports among non-pregnant populations, the proportion of submicroscopic malaria among all malaria infections was higher in Asia and the Americas, where it was more common among non-Plasmodium falciparum malaria species.

In addition, researchers explored factors associated with submicroscopic malaria by geographic region and found that, among parasitaemic women in Africa, submicroscopic infections were more likely in multigravidae and older women, whereas in Asia and the Americas, only older age was a risk factor.

The study also showed that sulfadoxine-pyrimethamine resistance played a role in increasing the risk of submicroscopic malaria in African cohort studies. Researchers conclude that malaria control in pregnancy should target both microscopic and submicroscopic infections.

The full paper is available in the The Lancet.

Similar stories

New insights into cellular pH regulators could inform research into neurological disease and cancer

High-resolution structures of two proteins that regulate acidity inside cells reveal how they interact with ions and membrane lipids, providing new insights into their roles in disease and potential avenues for drug discovery.

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.